Literature DB >> 31851913

Inhibition of Plasmepsin V Activity Blocks Plasmodium falciparum Gametocytogenesis and Transmission to Mosquitoes.

Charlie Jennison1, Leonardo Lucantoni2, Matthew T O'Neill3, Robyn McConville1, Sara M Erickson1, Alan F Cowman1, Brad E Sleebs1, Vicky M Avery2, Justin A Boddey4.   

Abstract

Plasmodium falciparum gametocytes infect mosquitoes and are responsible for malaria transmission. New interventions that block transmission could accelerate malaria elimination. Gametocytes develop within erythrocytes and activate protein export pathways that remodel the host cell. Plasmepsin V (PMV) is an aspartyl protease that is required for protein export in asexual parasites, but its function and essentiality in gametocytes has not been definitively proven, nor has PMV been assessed as a transmission-blocking drug target. Here, we show that PMV is expressed and can be inhibited specifically in P. falciparum stage I-II gametocytes. PMV inhibitors block processing and export of gametocyte effector proteins and inhibit development of stage II-V gametocytes. Gametocytogenesis in the presence of sublethal inhibitor concentrations results in stage V gametocytes that fail to infect mosquitoes. Therefore, PMV primes gametocyte effectors for export, which is essential for the development and fitness of gametocytes for transmission to mosquitoes.
Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  PEXEL; drug; effector protein; export; gametocyte; inhibitor; malaria; remodeling; sexual stage; transmission blocking

Mesh:

Substances:

Year:  2019        PMID: 31851913     DOI: 10.1016/j.celrep.2019.11.073

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  7 in total

Review 1.  Malaria parasite plasmepsins: More than just plain old degradative pepsins.

Authors:  Armiyaw S Nasamu; Alexander J Polino; Eva S Istvan; Daniel E Goldberg
Journal:  J Biol Chem       Date:  2020-05-04       Impact factor: 5.157

Review 2.  Recent metabolomic developments for antimalarial drug discovery.

Authors:  Lúcia Mamede; Fanta Fall; Matthieu Schoumacher; Allison Ledoux; Pascal De Tullio; Joëlle Quetin-Leclercq; Michel Frédérich
Journal:  Parasitol Res       Date:  2022-10-04       Impact factor: 2.383

Review 3.  Targeting the Plasmodium falciparum proteome and organelles for potential antimalarial drug candidates.

Authors:  James Abugri; Joseph Ayariga; Samuel Sunyazi Sunwiale; Cletus Adiyaga Wezena; Julien Agyemang Gyamfi; Michael Adu-Frimpong; Godfred Agongo; Julius Tieroyaare Dongdem; Daniel Abugri; Bismarck Dinko
Journal:  Heliyon       Date:  2022-08-24

4.  Tryptophan C-mannosylation is critical for Plasmodium falciparum transmission.

Authors:  Sash Lopaticki; Robyn McConville; Alan John; Niall Geoghegan; Shihab Deen Mohamed; Lisa Verzier; Ryan W J Steel; Cindy Evelyn; Matthew T O'Neill; Niccolay Madiedo Soler; Nichollas E Scott; Kelly L Rogers; Ethan D Goddard-Borger; Justin A Boddey
Journal:  Nat Commun       Date:  2022-07-29       Impact factor: 17.694

5.  The Medicines for Malaria Venture Malaria Box contains inhibitors of protein secretion in Plasmodium falciparum blood stage parasites.

Authors:  Oliver Looker; Madeline G Dans; Hayley E Bullen; Brad E Sleebs; Brendan S Crabb; Paul R Gilson
Journal:  Traffic       Date:  2022-08-15       Impact factor: 6.144

Review 6.  Protease Inhibition-An Established Strategy to Combat Infectious Diseases.

Authors:  Daniel Sojka; Pavla Šnebergerová; Luïse Robbertse
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

7.  Assessment of Biological Role and Insight into Druggability of the Plasmodium falciparum Protease Plasmepsin V.

Authors:  Alexander J Polino; Armiyaw S Nasamu; Jacquin C Niles; Daniel E Goldberg
Journal:  ACS Infect Dis       Date:  2020-02-27       Impact factor: 5.084

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.